{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:03:02Z","timestamp":1784048582473,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1053\/j.semnuclmed.2020.02.006","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T07:45:27Z","timestamp":1582962327000},"page":"162-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Targets for Therapy of Bladder Cancer"],"prefix":"10.1053","volume":"50","author":[{"given":"Christof","family":"Seidl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0001","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.urolonc.2019.05.021","article-title":"The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review","volume":"37","author":"Iwata","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0002","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0003","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1158\/1078-0432.CCR-17-1082","article-title":"Preclinical evaluation of intravesical cisplatin nanoparticles for non-muscle-invasive bladder cancer","volume":"23","author":"Kates","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/iju.13404","article-title":"Cancer stem cells and epithelial-mesenchymal transition in urothelial carcinoma: Possible pathways and potential therapeutic approaches","volume":"25","author":"Fang","year":"2018","journal-title":"Int J Urol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","article-title":"High risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage","volume":"17","author":"Veeratterapillay","year":"2016","journal-title":"Curr Urol Rep"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0006","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol."},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0007","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11255-019-02183-5","article-title":"Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics","volume":"51","author":"\u015alusarczyk","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.juro.2016.02.3005","article-title":"Immunotherapy for the treatment of urothelial carcinoma","volume":"197","author":"Donin","year":"2017","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0009","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.euo.2018.05.011","article-title":"From clinical trials to real-life clinical practice: The role of immunotherapy with PD-1\/PD-L1 inhibitors in advanced urothelial carcinoma","volume":"1","author":"Hussain","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2019.05.002","article-title":"PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis","volume":"76","author":"Ghate","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0011","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2019.05.041","article-title":"Safe use of immune checkpoint inhibitors in the multidisciplinary management of urological cancer: The European Association of Urology Position in 2019","volume":"76","author":"Grimm","year":"2019","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0012","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41585-019-0195-1","article-title":"Long non-coding RNAs in genitourinary malignancies: a whole new world","volume":"16","author":"Flippot","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0013","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13014-017-0802-3","article-title":"Down- regulation of LncRNA TUG1 enhances radiosensitivity in bladder cancer via suppressing HMGB1 expression","volume":"12","author":"Jiang","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0014","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nbt.2158","article-title":"Inhibition of natural antisense transcripts in vivo results in gene- specific transcriptional upregulation","volume":"30","author":"Modarresi","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0015","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.7150\/jca.31361","article-title":"MiR-27a: A novel biomarker and potential therapeutic target in tumors","volume":"10","author":"Li","year":"2019","journal-title":"J Cancer"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0016","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1158\/1078-0432.CCR-13-2805","article-title":"Reduced expression of mirna-27a modulates cisplatin resistance in bladder cancer by targeting the cystine\/glutamate exchanger slc7a11","volume":"20","author":"Drayton","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0017","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/ijms17010043","article-title":"Bladder cancer stem-Like cells: Their origin and therapeutic perspectives","volume":"17","author":"Ohishi","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0018","doi-asserted-by":"crossref","first-page":"E732","DOI":"10.3390\/cancers11050732","article-title":"Targeting cancer stem cells: A strategy for effective eradication of cancer","volume":"11","author":"Shibata","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: How does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0020","article-title":"Tumor M2-PK: A novel urine marker of bladder cancer","volume":"14","author":"Liu","year":"2019","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0021","doi-asserted-by":"crossref","first-page":"45983","DOI":"10.1038\/srep45983","article-title":"Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0022","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdw608","article-title":"A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer","volume":"28","author":"Belani","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0023","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/BLC-190211","article-title":"A clinical trial of the intradermal TLR2 agonist CADI-05 for BCG recurrent and unresponsive non-muscle invasive bladder cancer","volume":"5","author":"O'Donnell","year":"2019","journal-title":"Bladder Cancer"},{"issue":"suppl_15","key":"10.1053\/j.semnuclmed.2020.02.006_bib0024","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2018.36.15_suppl.4504","article-title":"Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)","volume":"36","author":"Rosenberg","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11864-019-0665-y","article-title":"Role of targeted therapies in management of metastatic urothelial cancer in the era of immunotherapy","volume":"20","author":"Grivas","year":"2019","journal-title":"Curr Treat Opt Oncol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0026","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signaling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0027","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1517\/13543784.2015.1041588","article-title":"Targeting the VEGF pathway in metastatic bladder cancer","volume":"24","author":"Mazzola","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0028","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-1-4939-7234-0_23","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in bladder cancer","volume":"1655","author":"Sathe","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0029","doi-asserted-by":"crossref","first-page":"e65257","DOI":"10.1371\/journal.pone.0065257","article-title":"Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: A novel strategy for treatment","volume":"8","author":"Nassim","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/BLC-180196","article-title":"Systematic review: targeting HER2 in bladder cancer","volume":"5","author":"Koshkin","year":"2019","journal-title":"Bladder Cancer"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0031","doi-asserted-by":"crossref","first-page":"48905","DOI":"10.18632\/oncotarget.16554","article-title":"HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts","volume":"8","author":"Eriksson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0032","first-page":"67","article-title":"Complications of radical cystectomy","volume":"59","author":"Buscarini","year":"2007","journal-title":"Minerva Urol Nefrol"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0033","first-page":"4157","article-title":"Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth","volume":"62","author":"Cheng","year":"2002","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0034","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1464-410X.2005.05497.x","article-title":"Expression of epidermal growth factor receptor family in normal and malignant urothelium","volume":"95","author":"Rotterud","year":"2005","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/imt.14.16","article-title":"Radioimmunotherapy with \u03b1-particle-emitting radionuclides","volume":"6","author":"Seidl","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0036","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","article-title":"Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting \u03b1-particles or Auger electrons","volume":"109","author":"Aghevlian","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0037","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with 225Actinium and 213Bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr Radiopharm"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0038","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1158\/0008-5472.CAN-06-3569","article-title":"Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells","volume":"67","author":"Friesen","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0039","doi-asserted-by":"crossref","first-page":"e64730","DOI":"10.1371\/journal.pone.0064730","article-title":"Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation","volume":"8","author":"Wulbrand","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0040","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.2967\/jnumed.109.065961","article-title":"Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice","volume":"50","author":"Pfost","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0041","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1080\/15384047.2015.1071735","article-title":"Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma","volume":"16","author":"Fazel","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0042","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s00259-018-4003-6","article-title":"Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: A pilot study","volume":"45","author":"Autenrieth","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0043","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.semnuclmed.2008.05.001","article-title":"Risks to normal tissues from radionuclide therapy","volume":"38","author":"Meredith","year":"2008","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0044","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/s00259-019-04354-z","article-title":"Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0045","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0046","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2967\/jnumed.117.190124","article-title":"The future of radioligand therapy: \u03b1, \u03b2, or both?","volume":"58","author":"Haberkorn","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.02.006_bib0047","doi-asserted-by":"crossref","first-page":"14712","DOI":"10.1002\/anie.201709532","article-title":"An eighteen-membered macrocyclic ligand for Actinium-225 targeted alpha therapy","volume":"56","author":"Thiele","year":"2017","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299820300076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299820300076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:35:34Z","timestamp":1757543734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299820300076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0001299820300076"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.02.006","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targets for Therapy of Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}